Advertisement

FF-10501 induces caspase-8-mediated apoptotic and endoplasmic reticulum stress-mediated necrotic cell death in hematological malignant cells

  • Taichi MatsumotoEmail author
  • Shiro Jimi
  • Keisuke Migita
  • Kazuki Terada
  • Masayoshi Mori
  • Yasushi Takamatsu
  • Junji Suzumiya
  • Shuuji Hara
Original Article
  • 31 Downloads

Abstract

FF-10501 is a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH). Clinical trials of FF-10501 for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are currently being conducted in the United States. Although it has been shown that FF-10501 induces apoptosis in hematological malignant cells, the intracellular mechanisms of this effect have not been characterized. We conducted an in vitro study to elucidate the mechanisms of FF-10501-induced cell death using 12 hematological malignant cell lines derived from myeloid and lymphoid malignancies. FF-10501 suppressed the growth of each cell line in a dose-dependent manner. However, the clinically relevant dose (40 μM) of FF-10501 induced cell death in three cell lines (MOLM-13, OCI-AML3, and MOLT-3). Investigation of the cell death mechanism suggested that FF-10501 induces both apoptotic and necrotic cell death. FF-10501-induced apoptosis was mediated by caspase-8 activation followed by activation of the mitochondrial pathway in MOLM-13 and MOLT-3 cells. FF-10501 induced necrotic cell death via endoplasmic reticulum stress in OCI-AML3 cells. The present study is the first to identify intracellular pathways involved in FF-10501-induced cell death.

Keywords

FF-10501 Apoptosis Necrosis Caspase-8 Endoplasmic reticulum stress 

Notes

Acknowledgements

The authors would like to thank Miyuki Saisho, Eri Sakai-Nagamatsu, Misato Yagi, Mami Sato, Miku Kamekou, Ayaka Tsuzuki, Takafumi Kuroiwa, Midori Suekane, Kousuke Iwasaki, and Shuntarou Nakamura for their help with the experiments.

Author contributions

TM and SJ designed the research study. TM performed the experiments. TM, SJ, KT, and MM analyzed and interpreted the data. TM drafted the manuscript. SJ, KM, YT, JS, and SH revised the manuscript. SJ provided final approval of the current version for submission.

Funding

This research was partially supported by FUJIFILM Corporation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021–34.  https://doi.org/10.1182/blood-2013-09-381665.CrossRefGoogle Scholar
  2. 2.
    Yoshimi A, Abdel-Wahab O. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. Int J Hematol. 2017;105(6):720–31.  https://doi.org/10.1007/s12185-017-2242-0.CrossRefGoogle Scholar
  3. 3.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.  https://doi.org/10.1016/S1470-2045(09)70003-8.CrossRefGoogle Scholar
  4. 4.
    Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903–28.  https://doi.org/10.1021/cr900021w.CrossRefGoogle Scholar
  5. 5.
    Collart FR, Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem. 1988;263(30):15769–72.Google Scholar
  6. 6.
    Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265(9):5292–5.Google Scholar
  7. 7.
    Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 1975;256(5515):331–3.CrossRefGoogle Scholar
  8. 8.
    Senda M, Natsumeda Y. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci. 1994;54(24):1917–26.CrossRefGoogle Scholar
  9. 9.
    Fukui M, Inaba M, Tsukagoshi S, Sakurai Y. New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase. Cancer Res. 1982;42(3):1098–102.Google Scholar
  10. 10.
    Murase M, Iwamura H, Komatsu K, Saito M, Maekawa T, Nakamura T, et al. Lack of cross-resistance to FF-10501, an inhibitor of inosine-5′-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines. Pharmacol Res Perspect. 2016;4(1):e00206.  https://doi.org/10.1002/prp2.206.CrossRefGoogle Scholar
  11. 11.
    Ichii M, Oritani K, Murase M, Komatsu K, Yamazaki M, Kyoden R, et al. Molecular targeting of inosine-5′-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway. Leuk Lymphoma. 2018;59(2):448–59.  https://doi.org/10.1080/10428194.2017.1339878.CrossRefGoogle Scholar
  12. 12.
    Yang H, Fang Z, Wei Y, Bohannan ZS, Ganan-Gomez I, Pierola AA, et al. Preclinical activity of FF-10501-01, a novel inosine-5′-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res. 2017;59:85–92.  https://doi.org/10.1016/j.leukres.2017.05.016.CrossRefGoogle Scholar
  13. 13.
    Crowley LC, Marfell BJ, Scott AP, Waterhouse NJ. Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc. 2016;2016:11.  https://doi.org/10.1101/pdb.prot087288.Google Scholar
  14. 14.
    Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175–93.  https://doi.org/10.1038/s41580-018-0089-8.CrossRefGoogle Scholar
  15. 15.
    Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5(11):897–907.  https://doi.org/10.1038/nrm1496.CrossRefGoogle Scholar
  16. 16.
    Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13(15):1899–911.CrossRefGoogle Scholar
  17. 17.
    Vercammen D, Vandenabeele P, Beyaert R, Declercq W, Fiers W. Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells. Cytokine. 1997;9(11):801–8.  https://doi.org/10.1006/cyto.1997.0252.CrossRefGoogle Scholar
  18. 18.
    Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460–70.  https://doi.org/10.1016/j.bbamcr.2013.06.028.CrossRefGoogle Scholar
  19. 19.
    Malek K, Boosalis MS, Waraska K, Mitchell BS, Wright DG. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leuk Res. 2004;28(11):1125–36.  https://doi.org/10.1016/j.leukres.2004.03.003.CrossRefGoogle Scholar
  20. 20.
    Kozhevnikova EN, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WF, Moshkin YM, et al. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell. 2012;47(1):133–9.  https://doi.org/10.1016/j.molcel.2012.04.030.CrossRefGoogle Scholar
  21. 21.
    Kokeny S, Papp J, Weber G, Vaszko T, Carmona-Saez P, Olah E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res. 2009;29(6):1971–80.Google Scholar
  22. 22.
    Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sanchez-Martin M, Madubata CJ, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018;553(7689):511–4.  https://doi.org/10.1038/nature25186.CrossRefGoogle Scholar
  23. 23.
    Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, et al. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005;24(38):5888–96.  https://doi.org/10.1038/sj.onc.1208739.CrossRefGoogle Scholar
  24. 24.
    Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE. 2006;2006(358):pe44.  https://doi.org/10.1126/stke.3582006pe44.CrossRefGoogle Scholar
  25. 25.
    Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999;13(19):2514–26.CrossRefGoogle Scholar
  26. 26.
    Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem. 2003;278(51):51613–21.  https://doi.org/10.1074/jbc.M305633200.CrossRefGoogle Scholar
  27. 27.
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181–90.CrossRefGoogle Scholar
  28. 28.
    Jonsson CA, Carlsten H. Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice. Clin Exp Immunol. 2001;124(3):486–91.CrossRefGoogle Scholar
  29. 29.
    Liao LX, Song XM, Wang LC, Lv HN, Chen JF, Liu D, et al. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy. Proc Natl Acad Sci USA. 2017;114(29):E5986–94.  https://doi.org/10.1073/pnas.1706778114.CrossRefGoogle Scholar
  30. 30.
    Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999;93(9):3053–63.Google Scholar
  31. 31.
    Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene. 2000;19(40):4563–73.  https://doi.org/10.1038/sj.onc.1203824.CrossRefGoogle Scholar
  32. 32.
    Chaigne-Delalande B, Guidicelli G, Couzi L, Merville P, Mahfouf W, Bouchet S, et al. The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal. J Immunol. 2008;181(11):7630–8.CrossRefGoogle Scholar
  33. 33.
    Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood. 2007;109(3):874–85.  https://doi.org/10.1182/blood-2006-07-012252.CrossRefGoogle Scholar
  34. 34.
    Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST, et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood. 2010;116(17):3286–96.  https://doi.org/10.1182/blood-2009-12-256149.CrossRefGoogle Scholar
  35. 35.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.  https://doi.org/10.1016/j.cell.2011.02.013.CrossRefGoogle Scholar
  36. 36.
    Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin Cell Dev Biol. 2014;35:51–6.  https://doi.org/10.1016/j.semcdb.2014.07.002.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Drug Informatics, Faculty of Pharmaceutical SciencesFukuoka UniversityFukuokaJapan
  2. 2.Central Laboratory of Pathology and Morphology, Department of MedicineFukuoka UniversityFukuokaJapan
  3. 3.Laboratory of Drug Design and Drug Delivery, Faculty of Pharmaceutical SciencesFukuoka UniversityFukuokaJapan
  4. 4.Department of Pharmacotherapeutics, Faculty of Pharmaceutical SciencesFukuoka UniversityFukuokaJapan
  5. 5.Division of Medical Oncology, Hematology, and Infectious Diseases, Department of MedicineFukuoka UniversityFukuokaJapan
  6. 6.Department of Oncology/HematologyShimane University HospitalShimaneJapan

Personalised recommendations